Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Freeport, Plains Exploration and the University of Texas: When is a Deal Too Close to Home?

Freeport, Plains Exploration and the University of Texas: When is a Deal Too Close to Home?Last week, Benzinga covered the Freeport-McMoRan Copper & Gold Inc. (NYSE:FCX) acquisitions of Mcmoran Exploration Co (NYSE:MMR) and Plains Exploration & Production Company (NYSE:PXP). After some more digging alongside Kai Petainen (SISU investor, contributor to Forbes and teacher of quant valuation at the Ross School of Business at the University of Michigan), there have been some answers but many more questions raised.

There were two curious relationships: Dr. Groat, a Professor at the University of Texas and an independent director to Plains Exploration; and BM Rankin Jr, the current Vice-Chairman of Freeport and a director at the University of Texas’ business school, according to multiple sources including Factset and the Wall Street Journal.

When reached for comment, the University denied that such a position exists, but admitted that an internal investigation has been launched into Dr. Groat’s dealings.

Groat has since resigned for his undisclosed conflict of interest: He released an industry report on fracking which argued that both fracking and horizontal drilling were safe. Groat was an independent director for an oil drilling company, so it raises many ethical, moral, and legal questions. However, the status of Rankin is also questionable.

As Petainen wrote earlier this week on his column on Forbes, the story gets even more interesting.

Petainen writes, “It has come to my attention that the CLL Global Research Foundation is linked to the University of Texas, and Rankin is a Director at the CLL Global Research Foundation.”

“According to the 2010 Form 990, 501c3 filing, [Dr. Michael J.] Keating is the CEO and President of CLL Global Research Foundation. The address listed on the form is ‘1515 Holcombe Blvd’, Houston TX. Where is 1515 Holcombe Boulevard? According to Google Maps, the dot appears directly over the University of Texas MD Anderson Cancer Center. So, according to the tax filings, the CLL Global Research Foundation home address is at the University of Texas.”

And then, listed in the Form 990 filing, we see “BM Rankin Jr Director.”

“Based on what I see in the data, in an effort to provide further clarification – Rankin is a Director at a Foundation, and that Foundation is located (as per tax forms) at the University of Texas,” Petainen notes.

The intricate web that has been cast amongst these directors and foundations appears to reach as far as the Boy Scouts of America in Texas. There is no data that says that these directors and executives acted fraudulently, but consider this: Plains CEO James Flores, who is also a Director at McMoRan Exploration, made nearly $20 million on his Plains stock. Flores owned 7,597 shares of McMoRan Exploration, whose shares also rallied nicely on the day the deal was announced.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.